Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
Key facts
- Where
- Québec, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Where in Canada
- IUCPQQuébec, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Josep Rodes-Cabau
- Trial code
- NCT04475510
- Record updated
- 4 November 2026
- Original description
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.Read full original descriptionShow less
Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke. The HALTI Trial
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Inclusion: Successful transcatheter PFO closure with any approved device; Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure.
Exclusion: Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency); Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia); Diabetes mellitus; Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure; Failure to provide signed informed consent; ->60 year-old; RoPE score <6; Residual shunt ≥moderate following PFO closure; Atrial fibrillation following PFO closure; Absolute contraindications for an MRI study.